MDGL
HOLD / NEUTRALMeanRevComposite
54.80
Technical
53.50
Fundamental
55.30
Rank
—
Price
493.11
Hurst
0.29
As of
Jul 31, 2026
Daily
Madrigal Pharmaceuticals, Inc.
HealthcareBiotechnologyMadrigal Pharmaceuticals is a biotech firm that develops treatments for metabolic dysfunction-associated steatohepatitis, a liver disease. The company's primary product is Rezdiffra, which works as a thyroid hormone receptor beta agonist designed specifically to address this condition. Founded in 2016 and based in Pennsylvania, the company operates in the United States market.
Market cap
$12.3B
P/E (trailing)
—
P/E (forward)
55.52
PEG ratio
—
Dividend yield
—
Beta
-0.99
52w range
393.61 – 615.00
Return on equity
-53.31%
Profit margin
-25.32%
Revenue growth
+71.20%
Earnings growth
—
Price history
1Y: 534.40 (+21.3%) · range 412.35–602.83
Cycle position
57/ 100 cycle scoreMID-BULL
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 13 · NOT READY · exit proximity 0
Conviction
21/ 100 · maturity 100%
VScore.403
Buildup.2039
EMA entry setup.2513
Fundamentals.1555
Volume profile
POC
516.02
Price vs POC
+3.6%
Overhead supply
23%
Runway
+0.3%
Value area 504.84–544.59 · 23% of 120d volume overhead · moderate overhead
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| earnings-surprise | 0.033 | Aug 28, 2026 |
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | +14.22% | +16.34% | mature |
| 40d | +14.37% | +17.04% | 29/40d |